Title: CRISPR protein inhibitors

Abstract

The embodiments disclosed herein utilize fluorescence polarization based preliminary screen to identify a putative set of Cas inhibitors from an initial set of candidate inhibitors. The primary screening assay is followed by secondary screening assay to validate the putative set of inhibitors selected by the preliminary screen. In some embodiments, the present disclosure includes compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors.

Inventors:

Choudhary, Amit; Cox, Kurt; Maji, Basudeb; Wu, Peng; Subramanian, Hari; Franco, Elisa

Issue Date:

2023-09-19

Research Org.:

The Broad Institute, Inc., Cambridge, MA (United States); Brigham and Women's Hospital (Harvard Medical School), Boston, MA (United States); Univ. of California, Riverside, MA (United States)

Sponsoring Org.:

USDOE; National Institutes of Health (NIH); Defense Advanced Research Projects Agency (DARPA); US Army Research Office (ARO)

OSTI Identifier:

2222337

Patent Number(s):

11760984

Application Number:

16/760,425

Assignee:

The Broad Institute, Inc. (Cambridge, MA); The Brigham and Women's Hospital, Inc. (Boston, MA); The Regents of the University of California (Oakland, CA)

DOE Contract Number:  

SC0010595; SC0010426; AI126239; N66001-17-2-4055; W911NF1610586

Resource Type:

Patent

Resource Relation:

Patent File Date: 10/31/2018

Country of Publication:

United States

Language:

English